Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: I. V. Kolyadina
Format: Artigo
Langue:Russo
Publié: ABV-press 2021-09-01
Collection:Opuholi Ženskoj Reproduktivnoj Sistemy
Sujets:
combined endocrine therapy
inhibitors cdk4/6
ribociclib
monaleesa-2
monaleesa-3
monaleesa-7
visceral crisis
Accès en ligne:https://ojrs.abvpress.ru/ojrs/article/view/845
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires